Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006269 · ClinicalTrials.gov registry record · Phase 3
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
A Phase 3 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
NCT00006269 is a Phase 3 study that was terminated before completion, run by Novartis. The registered enrollment target is 89 participants.
The verdict
NCT00006269, a Phase 3 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
Study Summary
RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are receiving irinotecan for metastatic colon cancer.
Interventions
- DRUG irinotecan hydrochloride
- DRUG octreotide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1999-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006269
The ClinicalTrials.gov registry entry for NCT00006269 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00006269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006269 about?
NCT00006269 is a clinical study titled "Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer". RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are receiving irinotecan for metastatic colon cancer.
What is the current status of trial NCT00006269?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 1999-12.
What interventions are being tested in trial NCT00006269?
The interventions under investigation include: irinotecan hydrochloride (DRUG), octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT00006269?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.